Fabrication and evaluation of centrifugal spun Miconazole-loaded sugar-based fibers

• Published in: Journal of drug delivery science and technology Vol. 98; p. 105872
• Main Authors: Alfassam, Haya A., Booq, Rayan Y., Almousained, Manal M., Alajmi, Areej M., Elfaky, Mahmoud A., Shaik, Rasheed A., Alsaleh, Nouf S., Aodah, Alhassan H., Alsulimani, Helal H., Halwani, Abdulrahman A., Alhindi, Yasser M., Alyamani, Essam J., Sirwi, Alaa, Tawfik, Essam A.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2024
• Subjects: Candida albicans; Centrifugal spinning; Miconazole; Microfibers; Oral candidiasis; Candida albicans; Centrifugal spinning; Miconazole; Oral candidiasis; Microfibers
• ISSN: 1773-2247
• DOI: 10.1016/j.jddst.2024.105872

Oral candidiasis is considered a very common infection in the oral cavity caused by Candida albicans (C. albicans). Miconazole is considered to be a very effective drug against many fungal infections but suffers from water insolubility and an unpleasant taste. Therefore, this study aims to prepare miconazole encapsulated into a sugar-based fibrous system composed of sucrose as the main component, along with polyvinylpyrrolidone (PVP) as a stabilizer, and miconazole using centrifugal spinning and to assess its antifungal activity in in vitro and in vivo mice models. The data showed that the miconazole-loaded fibers had a diameter of 6.6 ± 2.5 μm, an encapsulation efficiency % of 52 ± 4.5 %, a drug loading of 52 ± 4.5 μg/mg and full and rapid drug release after 4 h. The in vitro antifungal assessment exhibited that the miconazole-loaded fibers have a comparable antifungal activity to that of the positive control miconazole against two C. albicans strains. The in vivo mice oral candidiasis model demonstrated the ability of the miconazole-loaded fibers to inhibit C. albicans similarly to the commercially available product after 7 days of the treatment. Therefore, the miconazole-loaded fibers can be used as a potential alternative medication for oral candidiasis owing to its anti-Candida activity and its presence as a cotton-candy-like dosage form that would improve the children's acceptability and adherence. Further in vivo testing and long-term stability are required to ensure the safety, efficacy, and stability of this dosage form before its clinical application. [Display omitted]